Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Oric Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals reports enozertinib Phase 1b data and plans Phase 3 start in 2027

Positive Impact 4 of 5 product/contract Written later

ORIC Pharmaceuticals presented updated Phase 1b data for its enozertinib (ORIC-114) program at ESMO Congress 2026 on October 23, 2026, reporting an 84% investigator-assessed systemic response rate and a 70% investigator-assessed intracranial response rate in 26 patients with EGFR atypical NSCLC. The company plans to start a global Phase 3 trial, Redwood-1, in the first half of 2027. The filing contains clinical data only and no financial results, so the update's effect on shareholders depends on future trial outcomes and funding.

Key points

  • Investigator-assessed systemic ORR was 84% (21 of 25); BICR-assessed systemic ORR was 80% (20 of 25) as of the September 4, 2026 cutoff
  • BICR RANO-BM intracranial ORR was 67% (10 of 15), with a 40% (6 of 15) complete response rate
  • Six patients (23%) had Grade 3 treatment-related adverse events, all resolved with dose modifications; no Grade 4 or 5 events were reported
  • Redwood-1 Phase 3 trial plans to enroll approximately 360 patients, with initiation planned for the first half of 2027

The filing

CompanyOric Pharmaceuticals, Inc. (ORIC)
Form8-K, current report
Filed with the SECOct 23, 2026, 8:00 AM ET
Accession number0001193125-26-429465

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.